Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes.Oncogene. 2003; 22: 7687-7694
PRAME expression and clinical outcome of breast cancer.British Journal of Cancer. 2008; 99: 398-403
Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor.Immunity. 1997; 6: 199-208
The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.Clinical Cancer Research. 2004; 10: 4307-4313
PRAME gene expression in childhood acute lymphoblastic leukemia.Cancer Genetics and Cytogenetics. 2002; 138: 89-91
PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions.Oral Oncology. 2013; 49: 144-151
Expression and prognostic relevance of PRAME in primary osteosarcoma.Biochemical and Biophysical Research Communications. 2012; 419: 801-808
PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells.British Journal of Haematology. 1998; 102: 1376-1379
PRAME Gene Copy Number Variation Is Related to Its Expression in Multiple Myeloma.DNA and Cell Biology. 2017; 36: 1099-1107
The human tumor antigen repressor of retinoic acid PRAME is a dominant receptor signaling.Cell. 2005; 122: 835-847
PRAME: from diagnostic marker and tumor antigen to promising target of RNAi therapy in leukemic cells.Leukemia Research. 2011; 35: 1159-1160
Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.Clin Cancer Res. 2006; 12: 3130-3136
PRAME peptide-specific CD8(+) T cells represent the predominant response against leukemia-associated antigens in healthy individuals.Eur J Immunol. 2018; 48: 1400-1411
Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.Blood. 2003; 102: 2892-2900
Ex vivo characterization of polyclonal memory CD8(+) T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.Blood. 2009; 113: 2245-2255
Transferred WT1-Reactive CD8(+) T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients.Science Translational Medicine. 2013; 5: 174ra27
Transferred melanoma-specific CD8(+) T cells persist, mediate tumor regression, and acquire central memory phenotype.Proceedings of the National Academy of Sciences of the United States of America. 2012; 109: 4592-4597
Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study.Journal of Clinical Oncology. 2019; 37: 2349-2359
Complete Remissions Post Infusion of Multiple Tumor Antigen Specific T Cells for the Treatment of High Risk Leukemia and Lymphoma Patients after HCT.Blood. 2017; 130: 1
- Bach P.B.
- Giralt S.A.
- Saltz L.B.
FDA Approval of Tisagenlecleucel Promise and Complexities of a $475 000 Cancer Drug.JAMA. 2017; 318: 1861-1862
Manufacturing chimeric antigen receptor T cells: issues and challenges.Cytotherapy. 2019; 21: 327-340
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.Blood. 2013; 121: 5113-5123
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.Nat Med. 2006; 12: 1160-1166
Third-Party Donor Virus-Specific T Cells Are Efficacious in the Treatment of Refractory Viral Infection Following Allogeneic HSCT, but May Not Persist Post-Infusion.Blood. 2015; 126: 623
Efficient identification of novel HLA-A*0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.Journal of Experimental Medicine. 2001; 193: 73-88
- Kessler J.H.
- Melief C.J.M.
Identification of T-cell epitopes for cancer immunotherapy.Leukemia. 2007; 21: 1859-1874
High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.Blood. 2011; 117: 3353-3362
Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.Leukemia. 2013; 27: 1538-1547
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.Blood. 2009; 114: 1958-1967
A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer.Cancer Research. 2006; 66: 10639-10642
Insights on PRAME and osteosarcoma by means of gene expression profiling.Journal of Orthopaedic Science. 2011; 16: 458-466
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.Journal of Clinical Oncology. 2017; 35: 3547-3557
Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.Blood. 2007; 110: 1123-1131
Virus-specific T-cell therapies for patients with primary immune deficiency.Blood. 2020; 135: 620-628
Virus-specific T-cell banks for ‘off the shelf’ adoptive therapy of refractory infections.Bone Marrow Transplantation. 2016; 51: 1163-1172
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.Blood. 2008; 112: 1876-1885
Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration.Journal of Clinical Oncology. 2015; 33: 2999-3007
Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.Journal of Clinical Oncology. 2018; 36JCO1800076
An international strategy to determine the role of high dose therapy in recurrent Wilms’ tumour.European Journal of Cancer. 2013; 49: 194-210
CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.Sci Transl Med. 2015; 7: 285ra63
Tissue homing and persistence of defined antigen-specific CD8(+) tumor-reactive T-cell clones in long-term melanoma survivors.Journal of Investigative Dermatology. 2007; 127: 622-629
- Abdelaal H.M.
- Cartwright E.K.
- Skinner P.J.
Detection of Antigen-Specific T Cells Using In Situ MHC Tetramer Staining.International Journal of Molecular Sciences. 2019; 20: 11
Identification of peptide-specific TCR genes by in vitro peptide stimulation and CDR3 length polymorphism analysis.Cancer Letters. 2015; 363: 83-91
- Rego R.T.
- Morris E.C.
- Lowdell M.W.
T-cell receptor gene-modified cells: past promises, present methodologies and future challenges.Cytotherapy. 2019; 21: 341-357
Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.Oncology Research and Treatment. 2017; 40: 682-690
Identification of HLA class I-restricted tumor-associated antigens in adult T cell leukemia cells by mass spectrometric analysis.Experimental Hematology. 2006; 34: 1496-1504
- Castellino F.
- Germain R.N.
Cooperation between CD4(+) and CD8(+) T cells: when, where, and how.Annual Review of Immunology. 2006; 24: 519-540
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.Nature. 1998; 393: 480-483
- Maiers M.
- Gragert L.
- Klitz W.
High resolution HLA alleles and haplotypes in the US population.Human Immunology. 2006; 67: S16